Towards a comprehensive understanding of NMOSD
Prof. Hans-Peter Hartung was questioned about his views on NMOSD diagnosis and therapy and on the latest results from the N-Momentum trial, that evaluated the impact of B-cell depletion in NMOSD.
Read more
Exploring the benefits of inebilizumab treatment in NMOSDB-cell-depleting therapies, such as inebilizumab, represent a tool to tackle the possible source of autoimmune activity in NMOSD. It appears to be effective in reducing the risk of attack, disability, and pain in patients with NMOSD.
Read more
